A Clinical Decision Tool for Risk Stratifying Patients with Systemic Sclerosis-Related Pulmonary Hypertension
Authors:
- Justin K. LuiJLJustin K. Lui
- Kari R. GillmeyerKGKari R. Gillmeyer
- Ruchika A. SanganiRSRuchika A. Sangani
- Robert J. SmythRSRobert J. Smyth
- Deepa M. GopalDGDeepa M. Gopal
- Marcin A. TrojanowskiMTMarcin A. Trojanowski
- Andreea M. BujorABAndreea M. Bujor
- Renda Soylemez WienerRWRenda Soylemez Wiener
- Michael P. LaValleyMLMichael P. LaValley
- Elizabeth S. KlingsEKElizabeth S. Klings
- 13 November 2023
- journal article
- research article
- Published by Springer Nature in Lung
- Vol. 201 (6) , 565-569
Abstract
We devised a scoring system to identify patients with systemic sclerosis (SSc) at risk for pulmonary hypertension (PH) and predict all-cause mortality. Using 7 variables obtained via pulmonary function testing, echocardiography, and computed tomographic chest imaging, we applied the score to a retrospective cohort of 117 patients with SSc. There were 60 (51.3%) who were diagnosed with PH by right heart catheterization. Using a scoring threshold ≥ 0, our decision tool predicted PH with a sensitivity, specificity, and accuracy of 0.87 (95% CI 0.75, 0.94), 0.74 (95% CI 0.60, 0.84), and 0.80 (95% CI 0.72, 0.87), respectively. When adjusted for age at PH diagnosis, sex, and receipt of pulmonary arterial vasodilators, each one-point score increase was associated with an adjusted HR of 1.19 (95% CI 1.05, 1.34) for all-cause mortality. With further validation in external cohorts, our simplified clinical decision tool may better streamline earlier detection of PH in SSc.Keywords
Funding Information
- United Therapeutics Corporation
- National Scleroderma Foundation
- American Heart Association (23CDA1052352)
- Parker B. Francis Fellowship
- National Center for Advancing Translational Sciences (1UL1TR001430, 1UL1TR001430)
- Doris Duke Charitable Foundation (2021261)
- John Templeton Foundation (62288)
- National Heart, Lung, and Blood Institute (1R01HL155955-01A1, 1UG3 HL143192-01A1)
- VA Boston Healthcare System
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (CCCR P30 AR072571)
- Health Resources and Services Administration (U1EMC27864‐08‐00)
- Bayer
- Novo Nordisk
- Novartis
This publication has 17 references indexed in Scilit:
- Clinical prediction rules: A systematic review of healthcare provider opinions and preferencesInternational Journal of Medical Informatics, 2019
- Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertensionEuropean Respiratory Journal, 2017
- Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT studyAnnals of the Rheumatic Diseases, 2014
- Systemic Sclerosis-Associated Pulmonary Arterial HypertensionChest, 2013
- The Diagnostic Accuracy of Doppler Echocardiography in Assessment of Pulmonary Artery Systolic Pressure: A Meta‐AnalysisEchocardiography, 2012
- Improving the detection of pulmonary hypertension in systemic sclerosis using pulmonary function testsArthritis & Rheumatism, 2011
- Pulmonary Artery Acceleration Time Provides an Accurate Estimate of Systolic Pulmonary Arterial Pressure during Transthoracic EchocardiographyJournal of the American Society of Echocardiography, 2011
- Inaccuracy of Doppler Echocardiographic Estimates of Pulmonary Artery Pressures in Patients With Pulmonary HypertensionChest, 2011
- Changes in causes of death in systemic sclerosis, 1972–2002Annals of the Rheumatic Diseases, 2007
- Index for rating diagnostic testsCancer, 1950